Dr. Libby is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9333 Genesee Ave
San Diego, CA 92121Phone+1 800-926-8273
Summary
- Dr. Libby received his B.S. from the University of Texas at El Paso and his M.D. from the University of Texas Health Science Center at Houston. He completed his Internal Medicine residency and chief residency at the University of New Mexico(UNM) in Albuquerque. He was a Fellow in Hematology at UNM and at UNC Chapel Hill.
Education & Training
- University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
- University of New Mexico School of MedicineResidency, Internal Medicine, 1984 - 1987
- McGovern Medical School at UTHealthClass of 1984
Certifications & Licensure
- CA State Medical License 2024 - 2026
- WA State Medical License 2011 - 2026
- OR State Medical License 2023 - 2025
- WI State Medical License 2024 - 2025
- DC State Medical License 2022 - 2024
- NM State Medical License 1985 - 2013
- American Board of Internal Medicine Hematology
Clinical Trials
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 2 citationsBiomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee
Blood Advances. 2024-04-09 - 11 citationsSingle-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha
Cancer. 2023-12-01 - 10 citationsZanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee
Journal of Clinical Oncology. 2023-11-20
Abstracts/Posters
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Treating Cancer Differently in Older PatientsSeptember 10th, 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: